14 YEARS OF EXPERIENCE IN THE BUSINESS
Cordlife Group Limited (“Cordlife”, together with its
subsidiaries, the “Group”) is a consumer healthcare company
catering to the mother and child segment. Established in
May 2001 and successfully listed on March 29, 2012, the
Group is a pioneer in the provision of cord blood and cord
lining banking services.
LEADING THE WAY IN ASIA
Cordlife is amongst the leading players for private cord
blood banking services in all the markets it operates in,
namely Singapore, Indonesia, the Philippines, Hong Kong
and India. Inhabiting a distinctive niche in the healthcare
industry, the Group is one of the foremost private cord
blood banks to have gained a solid foothold in Asia. In
the last 14 years, Cordlife has dedicated its undertakings
with the aim of positioning itself as a market leader in the
industry. Having built a distinguished brand name for itself,
the Group continues to strive for excellence by means of
support from its experienced management team, dynamic
key executives along with its quality product and service
offerings. Cordlife believes it has in place a strong foundation
for future expansion.
BUILDING THE CORDLIFE BRAND
At Cordlife, we understand that having a unique and
memorable brand helps create a long-term position in the
marketplace. Hence, creating brand and market awareness
is a fundamental practice in sustaining the Group’s growth
in scale. This year, the Group has invested significantly in
various campaigns in all its operating markets such as the
hosting of talks to educate families about the importance of
storing their children’s cord blood and cord lining. In India,
television commercials were aired for the first time as part of
a through-the-line integrated marketing strategy to create
market awareness and grow market share, in addition to
other marketing initiatives such as digital marketing.
Aside from organic growth strategies to enhance brand
awareness in key markets, Cordlife also adopts inorganic
growth strategies through partnerships, joint ventures and
acquisitions. In October 2013, the Group acquired a 19.92%
stake, which was subsequently increased to approximately
31.81% in December 2013, in StemLife, a Ministry of Health,
Malaysia-licensed cord blood banking facility listed on the
ACE Market of Bursa Malaysia. In addition to that, Cordlife
has 7,314,015 ordinary shares, representing a 9.13% direct
stake, in CCBC. CCBC is the largest cord blood bank operator
in China, holding majority shares in the Beijing, Guangdong
and Zhejiang Cord Blood Banks, and approximately 24%
share in Shandong Cord Blood Bank. In November 2014,
Cordlife acquired, for US$44 million, a 7% senior unsecured
convertible note due October 3
,
2017 issued by CCBC (the
“CCBC Convertible Note”) in the principal amount of US$25
million. In May 2015, Cordlife entered into a conditional
purchase agreement with Golden Meditech Holdings
Limited (“Golden Meditech”), in which Golden Meditech
would purchase from Cordlife, the entire direct stake in CCBC
and the CCBC Convertible Note.
EXPANDING THE SCOPE OF OUR PRODUCT
AND SERVICE PORTFOLIO
Cordlife places utmost importance in growing its scope to
deliver quality products and services to its clients. The Group
introduced cord lining banking, the first complementary
service outside its core cord blood banking service in March
2011 in Hong Kong. Building on this focus, the service
was subsequently offered to parents in Singapore and
the Philippines in 2013. Today, this service is offered by all
Cordlife subsidiaries including India and Indonesia. The
Group also sub-licensed the service to CCBC and StemLife so
that both corporations can avail the service to their clients in
their respective territories.
4
CORDLIFE GROUP LIMITED
| ANNUAL REPORT 2015
CORPORATE
PROFILE
